drugset / Trial / NCT06179511
Study of AZD9829 in CD123+ Hematological Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematological malignancies.
Timeline
- Start
- 2024-01-31
- Primary completion
- 2025-10-31
- Completion
- 2026-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD9829 | Unknown | — | Intravenous |